Joel Greenblatt's BIO Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 124,626 shares of Bio-Rad Laboratories, Inc. (BIO) worth $34.94 M, representing 0.15% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in BIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 236,762 shares. Largest reduction occurred in Q2 2015, reducing 174,636 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +4,212 | New Buy | 4,212 | $113.49 |
| Q4 2014 | +236,762 | Add 5621.13% | 240,974 | $120.56 |
| Q1 2015 | +57,943 | Add 24.05% | 298,917 | $135.18 |
| Q2 2015 | -174,636 | Reduce 58.42% | 124,281 | $150.61 |
| Q3 2015 | -8,510 | Reduce 6.85% | 115,771 | $134.31 |
| Q4 2015 | -24,484 | Reduce 21.15% | 91,287 | $138.66 |
| Q1 2016 | -23,582 | Reduce 25.83% | 67,705 | $136.73 |
| Q2 2016 | -67,705 | Sold Out | 67,705 | $0.00 |
| Q3 2018 | +7,002 | New Buy | 7,002 | $313.05 |
| Q4 2018 | +401 | Add 5.73% | 7,403 | $232.20 |
| Q1 2019 | -5,026 | Reduce 67.89% | 2,377 | $305.85 |
| Q2 2019 | +4,731 | Add 199.03% | 7,108 | $312.61 |
| Q3 2019 | +11,411 | Add 160.54% | 18,519 | $332.74 |
| Q4 2019 | +1,498 | Add 8.09% | 20,017 | $370.04 |
| Q1 2020 | -1,947 | Reduce 9.73% | 18,070 | $350.58 |
| Q2 2020 | -3,189 | Reduce 17.65% | 14,881 | $451.52 |
| Q3 2020 | -12,613 | Reduce 84.76% | 2,268 | $515.43 |
| Q4 2020 | -620 | Reduce 27.34% | 1,648 | $583.13 |
| Q1 2021 | +4,376 | Add 265.53% | 6,024 | $571.22 |
| Q2 2021 | -3,233 | Reduce 53.67% | 2,791 | $644.21 |
| Q3 2021 | -1,269 | Reduce 45.47% | 1,522 | $745.73 |
| Q4 2021 | +6,125 | Add 402.43% | 7,647 | $755.59 |
| Q1 2022 | -1,035 | Reduce 13.53% | 6,612 | $563.22 |
| Q2 2022 | -3,236 | Reduce 48.94% | 3,376 | $494.96 |
| Q3 2022 | -1,465 | Reduce 43.39% | 1,911 | $417.06 |
| Q4 2022 | +144 | Add 7.54% | 2,055 | $420.49 |
| Q1 2023 | +768 | Add 37.37% | 2,823 | $479.02 |
| Q2 2023 | +1,957 | Add 69.32% | 4,780 | $379.12 |
| Q3 2023 | +17,891 | Add 374.29% | 22,671 | $358.45 |
| Q4 2023 | +14,743 | Add 65.03% | 37,414 | $322.89 |
| Q1 2024 | -4,028 | Reduce 10.77% | 33,386 | $345.87 |
| Q2 2024 | -4,690 | Reduce 14.05% | 28,696 | $273.11 |
| Q3 2024 | -10,552 | Reduce 36.77% | 18,144 | $334.58 |
| Q4 2024 | +3,805 | Add 20.97% | 21,949 | $328.51 |
| Q1 2025 | +6,517 | Add 29.69% | 28,466 | $243.56 |
| Q2 2025 | +59,397 | Add 208.66% | 87,863 | $241.32 |
| Q3 2025 | +36,763 | Add 41.84% | 124,626 | $280.39 |
Joel Greenblatt's Bio-Rad Laboratories Investment FAQs
Joel Greenblatt first purchased Bio-Rad Laboratories, Inc. (BIO) in Q3 2014, acquiring 4,212 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Bio-Rad Laboratories, Inc. (BIO) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q4 2014, adding 240,974 shares worth $29.05 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 124,626 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $34.94 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.15% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 298,917 shares, as reported at the end of Q1 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.